Sec. 5. National surveillance program for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
256 words·~1 min read·
/bill/116/hr/8658/ih/section-5A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, shall establish a program to provide for surveillance on the prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States. The program established under subsection
(a)shall include, at a minimum, each of the following surveillance activities: Conducting local surveillance activities to collect data on the prevalence and severity of nonalcoholic fatty level disease and nonalcoholic steatohepatitis. Compiling and annually publishing data on the number of individuals with nonalcoholic fatty level disease and nonalcoholic steatohepatitis nationally as well as in each state. To the extent practicable, providing data on the general population at risk of developing the conditions. In carrying out the program under subsection (a), the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, shall issue guidance that provides technical assistance to health care providers and State and local health departments on best practices to ensure appropriate collection of vital statistics for purposes of birth and death certificates, including vital statistics on populations with nonalcoholic fatty level disease and nonalcoholic steatohepatitis. There are authorized to be appropriated— to carry out surveillance activities described in subsection (b)(1), $10,000,000 for each of fiscal years 2021 and 2022; to carry out technical assistance activities described in subsection (b)(3), $10,000,000 for each of fiscal years 2021 and 2022; and to carry out the activities described in subsection (b)(2), $5,000,000 for each of fiscal years 2021 through 2025.